Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$8.81

-0.65 (-6.87%)

16:06
11/06/18
11/06
16:06
11/06/18
16:06

Iovance Biotherapeutics reports Q3 EPS (36c), consensus (33c)

At September 30, the company held $260M in cash, cash equivalents and short-term investments compared to $276.1M at June 30.

  • 06

    Nov

  • 20

    Nov

IOVA Iovance Biotherapeutics
$8.81

-0.65 (-6.87%)

09/25/18
COWN
09/25/18
NO CHANGE
COWN
Outperform
Iovance Biotherapeutics weakness a buying opportunity, says Cowen
Cowen analyst Boris Peaker said the recent weakness in Iovance is a buying opportunity. The analyst noted the company's results from the Moffitt-run study of TILS in NSCLC were deemed mild and somewhat disappointing. He believes the data has no read-through to the ongoing melanoma trial, making the weakness an attractive entry point. Peaker reiterated his Outperform rating on Iovance shares.
10/12/18
OPCO
10/12/18
NO CHANGE
Target $25
OPCO
Outperform
Iovance Biotherapeutics price target raised to $25 from $22 at Oppenheimer
Oppenheimer analyst Mark Breidenbach reiterated an Outperform rating on Iovance Biotherapeutics and raised his price target to $25 from $22 citing recent positive clinical updates for its tumor infiltrating lymphocyte product for melanoma and the outcome of discussions with the FDA regarding the regulatory pathway forward.
10/12/18
HCWC
10/12/18
NO CHANGE
HCWC
Iovance Biotherapeutics price target raised to $26 from $22 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Iovance Biotherapeutics and raised his price target on shares to $26 from $22, following the outcome of the end-of-Phase 2 meeting with the FDA regarding lead candidate LN-144. Pantginis called the interactions with the FDA "successful," and believes that Iovance will "further pursue its discussion with the agency in order to find the best path forward for LN-144 followed by assets across multiple indications." Additionally, the analyst reiterated his belief that Iovance is a compelling takeout candidate, and added that the company's cash resources provide strong leverage in any discussions.
11/06/18
WELS
11/06/18
NO CHANGE
WELS
Outperform
Iovance data supportive of potential approval, says Wells Fargo
The 38% response rate and duration greater than six months seen in this morning's abstract data for tumor-infiltrating lymphocyte therapeutic lifleucel in PD1 experienced metastatic melanoma are "highly differentiated from other cell therapies in solid tumors and supportive of potential approval if confirmed by pivotal study," Wells Fargo analyst Jim Birchenough tells investors in a research note. The analyst keeps an Outperform rating on shares of Iovance Biotherapeutics. The stock in morning trading is down 10%, or 99c, to $8.46.

TODAY'S FREE FLY STORIES

EOG

EOG Resources

$101.64

3.54 (3.61%)

06:57
11/16/18
11/16
06:57
11/16/18
06:57
Upgrade
EOG Resources rating change  »

EOG Resources upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$41.36

-0.045 (-0.11%)

06:56
11/16/18
11/16
06:56
11/16/18
06:56
Hot Stocks
AstraZeneca reports Phase 3 MYSTIC trial did not meet primary endpoints »

AstraZeneca and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

NVDA

Nvidia

$202.65

5.43 (2.75%)

06:55
11/16/18
11/16
06:55
11/16/18
06:55
Recommendations
Nvidia analyst commentary  »

Nvidia selloff an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

YNDX

Yandex

$29.40

0.48 (1.66%)

06:52
11/16/18
11/16
06:52
11/16/18
06:52
Periodicals
Yandex to launch online taxi-hailing service in Israel, Reuters reports »

Yandex's online…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$202.65

5.43 (2.75%)

06:52
11/16/18
11/16
06:52
11/16/18
06:52
Recommendations
Nvidia analyst commentary  »

Nvidia selloff today a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

JPM

JPMorgan

$110.07

2.71 (2.52%)

, V

Visa

$141.91

2.625 (1.88%)

06:51
11/16/18
11/16
06:51
11/16/18
06:51
Hot Stocks
Chase, Visa partner for contactless credit cards »

Chase (JPM) is teaming up…

JPM

JPMorgan

$110.07

2.71 (2.52%)

V

Visa

$141.91

2.625 (1.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 29

    Jan

  • 26

    Feb

NVDA

Nvidia

$202.65

5.43 (2.75%)

06:49
11/16/18
11/16
06:49
11/16/18
06:49
Recommendations
Nvidia analyst commentary  »

Nvidia price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

AMAT

Applied Materials

$35.03

1.44 (4.29%)

06:47
11/16/18
11/16
06:47
11/16/18
06:47
Recommendations
Applied Materials analyst commentary  »

Applied Materials price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFLT

PennantPark Floating Rate

$13.06

-0.08 (-0.61%)

06:43
11/16/18
11/16
06:43
11/16/18
06:43
Upgrade
PennantPark Floating Rate rating change  »

PennantPark Floating Rate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAH

Cardinal Health

$57.62

0.315 (0.55%)

06:42
11/16/18
11/16
06:42
11/16/18
06:42
Downgrade
Cardinal Health rating change  »

Cardinal Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

DB

Deutsche Bank

$9.89

0.03 (0.30%)

, BAC

Bank of America

$27.91

0.68 (2.50%)

06:41
11/16/18
11/16
06:41
11/16/18
06:41
Periodicals
Deutsche Bank, BofA, JPM contacted over Danske investigation, Bloomberg reports »

U.S. criminal…

DB

Deutsche Bank

$9.89

0.03 (0.30%)

BAC

Bank of America

$27.91

0.68 (2.50%)

JPM

JPMorgan

$110.07

2.71 (2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

  • 26

    Feb

HD

Home Depot

$177.36

-2.54 (-1.41%)

06:40
11/16/18
11/16
06:40
11/16/18
06:40
Downgrade
Home Depot rating change  »

Home Depot downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSM

Williams-Sonoma

$60.60

-1.16 (-1.88%)

06:38
11/16/18
11/16
06:38
11/16/18
06:38
Recommendations
Williams-Sonoma analyst commentary  »

Williams-Sonoma price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$143.86

-0.39 (-0.27%)

06:34
11/16/18
11/16
06:34
11/16/18
06:34
Periodicals
Facebook CEO says he was unaware of Definers Public Affairs hiring, BI reports »

Facebook CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

EMCI

EMC Insurance

$23.85

-0.07 (-0.29%)

06:33
11/16/18
11/16
06:33
11/16/18
06:33
Hot Stocks
EMCC proposes to acquire remaining shares of EMC Insurance for $30 per share »

Employers Mutual Casualty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$143.86

-0.39 (-0.27%)

06:25
11/16/18
11/16
06:25
11/16/18
06:25
Periodicals
Facebook faces renewed criticism from Washington after NYT story, Recode says »

Facebook is facing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

FUJHY

Subaru

$0.00

(0.00%)

06:25
11/16/18
11/16
06:25
11/16/18
06:25
Downgrade
Subaru rating change  »

Subaru downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSM

Williams-Sonoma

$60.60

-1.16 (-1.88%)

, RH

RH

$119.39

-4.73 (-3.81%)

06:24
11/16/18
11/16
06:24
11/16/18
06:24
Recommendations
Williams-Sonoma, RH analyst commentary  »

Williams-Sonoma price…

WSM

Williams-Sonoma

$60.60

-1.16 (-1.88%)

RH

RH

$119.39

-4.73 (-3.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMTOF

Mitsubishi Motors

$0.00

(0.00%)

06:23
11/16/18
11/16
06:23
11/16/18
06:23
Upgrade
Mitsubishi Motors rating change  »

Mitsubishi Motors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$143.86

-0.39 (-0.27%)

, PUBGY

Publicis

$0.00

(0.00%)

06:22
11/16/18
11/16
06:22
11/16/18
06:22
Periodicals
Facebook lack of morals drawing ire from advertisers, New York Times reports »

Facebook (FB) is coming…

FB

Facebook

$143.86

-0.39 (-0.27%)

PUBGY

Publicis

$0.00

(0.00%)

WPP

WPP

$55.45

-0.65 (-1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

EVKIF

Evonik

$0.00

(0.00%)

06:20
11/16/18
11/16
06:20
11/16/18
06:20
Downgrade
Evonik rating change  »

Evonik downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$0.00

(0.00%)

06:16
11/16/18
11/16
06:16
11/16/18
06:16
Periodicals
Volkswagen CEO to assume responsibility for China business, Reuters reports »

Volkswagen CEO Herbert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$202.65

5.43 (2.75%)

06:13
11/16/18
11/16
06:13
11/16/18
06:13
Recommendations
Nvidia analyst commentary  »

Nvidia price target cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

YEXT

Yext

$17.44

0.35 (2.05%)

06:08
11/16/18
11/16
06:08
11/16/18
06:08
Initiation
Yext initiated  »

Yext initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

PLUS

ePlus

06:07
11/16/18
11/16
06:07
11/16/18
06:07
Initiation
ePlus initiated  »

ePlus initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.